Centiva Capital LP Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Centiva Capital LP acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 9,151 shares of the specialty pharmaceutical company’s stock, valued at approximately $331,000.

Other hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $52,000. Headlands Technologies LLC boosted its holdings in shares of Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $72,000. Finally, Venturi Wealth Management LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth about $92,000.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Up 0.5%

Shares of SUPN opened at $31.70 on Monday. The company has a market capitalization of $1.77 billion, a PE ratio of 29.63 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock’s 50-day moving average price is $31.86 and its two-hundred day moving average price is $34.90.

Analyst Ratings Changes

Several research analysts have commented on the company. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.